Related references
Note: Only part of the references are listed.Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Kai Wang et al.
CLINICAL INFECTIOUS DISEASES (2021)
Asymptomatic Reinfection in 2 Healthcare Workers From India With Genetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2
Vivek Gupta et al.
CLINICAL INFECTIOUS DISEASES (2021)
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals
Alba Grifoni et al.
CELL (2020)
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein
Alexandra C. Walls et al.
CELL (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Serum IgA, IgM, and IgG responses in COVID-19
Huan Ma et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019
Juanjuan Zhao et al.
CLINICAL INFECTIOUS DISEASES (2020)
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients
Hai-qiong Yu et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset
Bin Lou et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Immunology of COVID-19: Current State of the Science
Nicolas Vabret et al.
IMMUNITY (2020)
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection
Paul Kellam et al.
JOURNAL OF GENERAL VIROLOGY (2020)
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Jingyou Yu et al.
SCIENCE (2020)
Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV
Xiuyuan Ou et al.
NATURE COMMUNICATIONS (2020)
Use of Saliva for Diagnosis and Monitoring the SARS-CoV-2: A General Perspective
Jose J. Ceron et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Rui Shi et al.
NATURE (2020)
Human neutralizing antibodies elicited by SARS-CoV-2 infection
Bin Ju et al.
NATURE (2020)
Antibody responses to SARS-CoV-2 in patients with COVID-19
Quan-Xin Long et al.
NATURE MEDICINE (2020)
TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
Ruochen Zang et al.
SCIENCE IMMUNOLOGY (2020)
Neutralizing Antibody Responses to Severe Acute Respiratory Syndrome Coronavirus 2 in Coronavirus Disease 2019 Inpatients and Convalescent Patients
Xiaoli Wang et al.
CLINICAL INFECTIOUS DISEASES (2020)
Improved clinical symptoms and mortality among patients with severe or critical COVID-19 after convalescent plasma transfusion
Xinyi Xia et al.
BLOOD (2020)
Use of convalescent plasma in hospitalized patients with COVID-19: case series
Livia Hegerova et al.
BLOOD (2020)
Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells
Yunlong Cao et al.
CELL (2020)
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies
Ahmed O. Hassan et al.
CELL (2020)
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Gabriel Dagotto et al.
CELL HOST & MICROBE (2020)
Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation
Emilie Seydoux et al.
IMMUNITY (2020)
The receptor-binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients
Lakshmanane Premkumar et al.
SCIENCE IMMUNOLOGY (2020)
A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Wafaa B. Alsoussi et al.
JOURNAL OF IMMUNOLOGY (2020)
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
Feng-Cai Zhu et al.
LANCET (2020)
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Pedro M. Folegatti et al.
LANCET (2020)
The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues
Jialu Qiao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Takuya Sekine et al.
CELL (2020)
Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity
Carolyn Rydyznski Moderbacher et al.
CELL (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Xiangyang Chi et al.
SCIENCE (2020)
Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies
Alina Baum et al.
SCIENCE (2020)
Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate
Amin Addetia et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2020)
Seasonal coronavirus protective immunity is short-lasting
Arthur W. D. Edridge et al.
NATURE MEDICINE (2020)
Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China
Fan Wu et al.
JAMA INTERNAL MEDICINE (2020)
Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement
Jinkai Zang et al.
CELL DISCOVERY (2020)
The Antibody Response to SARS-CoV-2 Infection
Linda Hueston et al.
OPEN FORUM INFECTIOUS DISEASES (2020)
Science in the time of coronavirus
[Anonymous]
NATURE METHODS (2020)
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients
Mehul S. Suthar et al.
CELL REPORTS MEDICINE (2020)
A real-time dashboard of clinical trials for COVID-19
Kristian Thorlund et al.
LANCET DIGITAL HEALTH (2020)
Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study
Brian Hanley et al.
LANCET MICROBE (2020)
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
Yushun Wan et al.
JOURNAL OF VIROLOGY (2019)
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
Li Liu et al.
JCI INSIGHT (2019)
Beyond binding: antibody effector functions in infectious diseases
Lenette L. Lu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Antibody-dependent enhancement of severe dengue disease in humans
Leah C. Katzelnick et al.
SCIENCE (2017)
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Qidi Wang et al.
ACS INFECTIOUS DISEASES (2016)
Middle East respiratory syndrome
Alimuddin Zumla et al.
LANCET (2015)
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Sheng-Fan Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Correlates of Protection Induced by Vaccination
Stanley A. Plotkin
CLINICAL AND VACCINE IMMUNOLOGY (2010)
Correlates of vaccine-induced immunity
Stanley A. Plotkin
CLINICAL INFECTIOUS DISEASES (2008)
Protective immunity following vaccination
Ian J. Amanna et al.
HUMAN VACCINES (2008)
Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome
N Lee et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Neutralizing antibody response and SARS severity
MS Ho et al.
EMERGING INFECTIOUS DISEASES (2005)
Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry
G Simmons et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Immune responses and disease enhancement during respiratory syncytial virus infection
PJM Openshaw et al.
CLINICAL MICROBIOLOGY REVIEWS (2005)
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses
ZY Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus
PR Hsueh et al.
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Kinetics of severe acute respiratory syndrome (SARS) coronavirus-specific antibodies in 271 laboratory-confirmed cases of SARS
ZP He et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2004)
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
WH Li et al.
NATURE (2003)
Share Paper
